SCHEMBL3010359

SCHEMBL3010359

Cc1ccccc1-c1csc(N2CCC(S(=O)(=O)c3cccc([N+](=O)[O-])c3)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.46
MAPT P10636 4/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 1/20 0.39
AR P10275 2/20 0.39
ACHE P22303 1/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4D Q08499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019498 0.94 SMN1; SMN2 (0.44) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3003083 0.91 AR (0.51) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3007511 0.91 NPC1 (0.42) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3016022 0.91 NPC1 (0.48) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3018960 0.89 SMN1; SMN2 (0.44) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3007090 0.88 SMN1; SMN2 (0.42) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL2998035 0.87 SMN1; SMN2 (0.53) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3013821 0.87 NPC1 (0.47) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3013943 0.86 SMN1; SMN2 (0.47) SMN1; SMN2MAPTMEN1KMT2ALMNA
SCHEMBL3009056 0.86 KMT2A (0.51) SMN1; SMN2MAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885MAPT 18/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.